Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FD5B8
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $65,851
Award facts
- Contract value 100% obligated
- $65,851.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $65,851.46 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 17, 2025, with completion targeted for July 18, 2025. This non-set-aside contract utilizes firm fixed pricing under a competitively awarded delivery order mechanism. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal medical procurement vendor for military and veteran healthcare systems. The company's extensive portfolio of federal contract awards demonstrates its capability to deliver specialized pharmaceuticals across multiple therapeutic domains, including biologics, specialty medications, and brand-name drugs. Under the DLA Troop Support Medical IDC, AmerisourceBergen supplies customers including the Defense Health Agency and U.S. Coast Guard. The current delivery order for Dupixent, a prescription biologic commonly used for dermatologic and respiratory conditions, represents one of numerous pharmaceutical transactions issued against this comprehensive global pharmaceutical support vehicle.
Quick answers
Who was awarded contract SPE2DB25FD5B8?
SPE2DB25FD5B8 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on July 17, 2025.
How much is contract SPE2DB25FD5B8 worth?
The government has obligated $65,851 on SPE2DB25FD5B8.
Is contract SPE2DB25FD5B8 an order under another contract?
Yes. SPE2DB25FD5B8 is a delivery order under SPE2DB20D1100, an indefinite delivery contract.
Was contract SPE2DB25FD5B8 competed?
The extent of competition for SPE2DB25FD5B8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award